Forefront Analytics’s Poseida Therapeutics PSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-27,855
Closed -$79.7K – 71
2024
Q3
$79.7K Sell
27,855
-1,962
-7% -$6.07K 0.04% 65
2024
Q2
$87.1K Buy
29,817
+3,037
+11% +$8.31K 0.04% 64
2024
Q1
$85.4K Buy
26,780
+1,311
+5% +$4.37K 0.04% 64
2023
Q4
$85.6K Buy
25,469
+500
+2% +$1.29K 0.04% 61
2023
Q3
$59.4K Sell
24,969
-1,650
-6% -$3.46K 0.03% 63
2023
Q2
$46.8K Buy
26,619
+11,579
+77% +$29.6K 0.03% 64
2023
Q1
$46.3K Sell
15,040
-230
-2% -$1.38K 0.02% 75
2022
Q4
$80.9K Sell
15,270
-380
-2% -$1.74K 0.04% 61
2022
Q3
$59K Sell
15,650
-7,720
-33% -$25.5K 0.03% 61
2022
Q2
$61K Sell
23,370
-3,400
-13% -$9.45K 0.03% 59
2022
Q1
$121K Buy
26,770
+16,150
+152% +$72.8K 0.04% 58
2021
Q4
$72K Buy
10,620
+275
+3% +$1.87K 0.02% 59
2021
Q3
$72K Buy
+10,345
New +$88.8K 0.03% 62

Other funds holding PSTX

Forefront Analytics's PSTX Position: Q4 2024 in Review

Forefront Analytics sold out of Poseida Therapeutics (PSTX) in Q4 2024, closing a stake of 27,855 shares — an estimated $79.7K sold.

Forefront Analytics first reported a position in PSTX in Q3 2021 and held it in 13 quarters. The position peaked at $121K in Q1 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Forefront Analytics reported no remaining Poseida Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Forefront Analytics sold 27,855 Poseida Therapeutics shares in Q4 2024, an estimated $79.7K.
  • Forefront Analytics first reported a position in Poseida Therapeutics in Q3 2021 and held it in 13 quarters.
  • Forefront Analytics's Poseida Therapeutics position peaked at $121K in Q1 2022.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics as of Q4 2024.

Based on Forefront Analytics's 13F filing for Q4 2024, filed 14 Feb 2025.